Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study

Background Colorectal cancer is known to be an extrahepatic complication of non-alcoholic fatty liver disease (NAFLD). However, the interaction of NAFLD with obesity for incident colorectal cancer has not been clarified yet. Moreover, the effect of NAFLD and obesity for incident gastric cancer has not been clarified yet. Thus, we investigated whether NAFLD with or without obesity would be a risk factor for incident gastric cancer as well as colorectal cancer. Methods The study period was set from 2003 to 2016. NAFLD was diagnosed by abdominal ultrasonography using standardised criteria. We applied the Cox proportional hazards model to investigate the effect of NAFLD with or without obesity at baseline on incident gastric cancer as well as colorectal cancer. Age, sex, lifestyle factors including smoking states, alcohol consumption and exercise, and diabetes were used as covariates. Results During the study period, 27 944 individuals (16 454 men and 11 490 women) were registered in the NAfld in Gifu Area, Longitudinal Analysis study. During the mean (SD) observational period of 2357 (1458) days, incident gastric cancers were diagnosed in 48 individuals (incident rate 0.48 per 1000 person-years) and incident colorectal cancers were diagnosed in 52 individuals (incident rate 0.51 per 1000 person-years). The adjusted HR of NAFLD with obesity for incident gastric cancer was 3.58 (95% CI 1.73 to 7.38, p=0.001) and that for incident colorectal cancer was 2.96 (95% CI 1.73 to 7.38, p=0.003). Conclusion NAFLD with obesity was a risk factor for both incident gastric cancer and colorectal cancer in apparently healthy Japanese individuals.

[1]  E. Bonora,et al.  Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.

[2]  V. Wong,et al.  Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment , 2018, Journal of gastroenterology and hepatology.

[3]  V. Wong,et al.  The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups , 2018, Journal of gastroenterology and hepatology.

[4]  C. Abnet,et al.  Body mass index and risk of gastric cancer: A 30‐year follow‐up study in the Linxian general population trial cohort , 2017, Cancer science.

[5]  E. Bugianesi,et al.  Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers , 2016, International journal of molecular sciences.

[6]  N. Nakamura,et al.  Triglycerides to high‐density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population‐based cohort study , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[7]  N. Nakamura,et al.  The impact of non‐alcoholic fatty liver disease on incident type 2 diabetes mellitus in non‐overweight individuals , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[8]  K. Hveem,et al.  Metabolic syndrome and esophageal and gastric cancer , 2015, Cancer Causes & Control.

[9]  E. Bugianesi,et al.  Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander , 2015, Seminars in Liver Disease.

[10]  N. Nakamura,et al.  Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study , 2015, Endocrine.

[11]  N. Nakamura,et al.  The modest alcohol consumption reduces the incidence of fatty liver in men: a population‐based large‐scale cohort study , 2015, Journal of gastroenterology and hepatology.

[12]  G. Tarantino,et al.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? , 2014, World journal of gastroenterology.

[13]  D. Giugliano,et al.  Metabolic Syndrome and Risk of Cancer , 2012, Diabetes Care.

[14]  I. Kamel,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[15]  H. Tilg,et al.  NAFLD and extrahepatic cancers: have a look at the colon , 2011, Gut.

[16]  E. Giovannucci,et al.  A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[17]  G. Perseghin.  Viewpoints on the Way to a Consensus Session , 2009, Diabetes Care.

[18]  M. Woodward,et al.  Obesity and Risk of Colorectal Cancer: A Meta-analysis of 31 Studies with 70,000 Events , 2007, Cancer Epidemiology Biomarkers & Prevention.

[19]  Yuichi Harano,et al.  The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reflects the Metabolic Syndrome and Visceral Fat Accumulation , 2007, The American Journal of Gastroenterology.

[20]  Alicja Wolk,et al.  Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. , 2007, The American journal of clinical nutrition.

[21]  T. Omatsu,et al.  The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease , 2006, Annals of Internal Medicine.

[22]  G. Marchesini,et al.  Insulin resistance: A metabolic pathway to chronic liver disease , 2005, Hepatology.

[23]  K. Lindor,et al.  Nonalcoholic fatty liver disease , 2005, Canadian Medical Association Journal.

[24]  A. McCullough,et al.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[25]  C. Caldas,et al.  A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. , 2003, Gastroenterology.

[26]  J. Goedert,et al.  Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. , 2003, Gastroenterology.

[27]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[28]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[29]  A. Peiris,et al.  Insulin: a novel factor in carcinogenesis. , 2002, The American journal of the medical sciences.

[30]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[31]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[32]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Granger,et al.  Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Waksman,et al.  CYTOTOXICITY MEDIATED BY SOLUBLE ANTIGEN AND LYMPHOCYTES IN DELAYED HYPERSENSITIVITY , 1968, The Journal of experimental medicine.

[35]  Yoosoo Chang,et al.  gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. , 2007, Clinical chemistry.